Olema Pharmaceuticals Inc. (OLMA)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Olema Pharmaceuticals, Inc. (OLMA) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript
Olema Pharmaceuticals, Inc. (OLMA) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript
Olema Pharmaceuticals, Inc. (OLMA) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript
Olema Pharmaceuticals, Inc. (OLMA) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript
Olema Pharmaceuticals, Inc. (OLMA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Olema Pharmaceuticals, Inc. (OLMA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Olema: 'Strong Buy' Maintained On OPERA-02 Trial Initiation & Additional Shots On Goal
Olema Pharmaceuticals (OLMA) earns a "Strong Buy" rating, driven by advancing palazestrant for 1st-line ER+/HER2- metastatic breast cancer in pivotal phase 3 trials. Company's palazestrant + KISQALI combination achieved a promising 15.5-month mPFS in heavily pretreated patients, addressing endocrine resistance in both ESR1-mutant and wild-type tumors. Key catalysts include OPERA-01 monotherapy data expected in 2H 2026 and OPERA-02 topline results in 2028, with potential NDA filing in 2027 for monotherapy if successful.
Wall Street Analysts Think Olema Pharmaceuticals (OLMA) Could Surge 433.13%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 433.1% in Olema Pharmaceuticals (OLMA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
After Plunging -30.16% in 4 Weeks, Here's Why the Trend Might Reverse for Olema Pharmaceuticals (OLMA)
The heavy selling pressure might have exhausted for Olema Pharmaceuticals (OLMA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Olema Pharmaceuticals: Maybe Not Differentiated, But Could Find A Niche In A Valuable Market
Olema Pharmaceuticals's palazestrant shows promise in late-stage trials for metastatic breast cancer, with potential FDA approval and commercial launch by 2027. Strong liquidity with $139.5 million in cash and $294.6 million in marketable securities, providing a cash runway of 4-4.5 years. Despite competition in the SERD space, OLMA's valuation is low at $200 million, suggesting potential for significant upside.
Recent Price Trend in Olema Pharmaceuticals (OLMA) is Your Friend, Here's Why
Olema Pharmaceuticals (OLMA) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
